Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps
Spinal muscular atrophy (SMA) is a recessive disorder caused by a mutation in the survival motor neuron 1 gene (SMN1); it affects 1 in 11 000 newborn infants. The most severe and most common form, type 1 SMA, is associated with early mortality in most cases and severe disability in survivors. Nusine...
Main Authors: | Gidaro, T, Servais, L |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado: |
Wiley
2018
|
Títulos similares
-
Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen
por: Aragon-Gawinska, K, et al.
Publicado: (2019) -
Nusinersen and spinal muscular atrophies: Where are we in 2020?
por: Satish V Khadilkar, et al.
Publicado: (2020-01-01) -
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
por: Finkel, RS, et al.
Publicado: (2017) -
Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients
por: Tommaso Nuzzo, et al.
Publicado: (2023-02-01) -
Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy
por: Benjamin Stolte, et al.
Publicado: (2018-10-01)